Background/Aim. Metabolic Bone disorders are well-recognized extrahepatic complications of cirrhosis. The aim was to report their prevalence and the associated factors to their development in patients with viral cirrhosis. Patients and Methods. All consecutive patients with viral cirrhosis were prospectively enrolled. Parathyroid hormone, 25-hydroxyvitamin D, liver function, and phosphocalcic tests were measured in all patients. Bone mineral density was measured at the lumbar spine and total hip by dual-energy X-ray absorptiometry. Data were analyzed using SPSS software. Results. Forty-six cirrhotic patients were included with hepatitis C (87%) and hepatitis B (13%). The Child-Pugh score was grade A in 87% of cases and grade B in 13%. Thirty-seven patients had decreased bone mineral density with osteopenia in 24 patients and osteoporosis in 13 patients. Decreased 25-hydroxyvitamin D was found in 95.6% of cases. Bone disorders were significantly more frequent in old patients with low body mass index, long duration of liver disease, and low 25-hydroxyvitamin D level. None of these factors was an independent factor associated with bone disorders. Conclusion. Our study revealed a high prevalence of metabolic bone disorders among viral cirrhotic patients. Consequently, bone mineral density assessment should be performed systematically in all cirrhotic patients. 1. Introduction The association between metabolic bone abnormalities and chronic liver disease is now well recognized. Often known as hepatic osteodystrophy, these disorders are a common complication of liver cirrhosis with a reported prevalence of 12% to 86% [1–4]. Osteoporosis is the well-known major complication of hepatic osteodystrophy. Its prevalence varies considerably and ranges from 20% to 50% [5]. It is related to the severity of cirrhosis and affects 38% of patients awaiting liver transplantation [6, 7]. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to bone fragility and increased fracture risk, a source of morbidity and mortality in patients already weakened by their chronic liver disease. The pathogenesis of bone demineralization in cirrhosis remains incompletely understood. It is most often multifactorial and many factors affecting directly or indirectly bone turnover have been implicated: insulin growth factor-I, interleukin-1, tumor necrosis factor-α, and osteoprotegerin, which promote osteoclastic bone resorption in addition to the receptor activator of NF kappa beta (RANK) and the receptor activator of NF kappa beta ligand
References
[1]
O. I. Giouleme, T. A. Vyzantiadis, N. L. Nikolaidis et al., “Pathogenesis of osteoporosis in liver cirrhosis,” Hepato-Gastroenterology, vol. 53, no. 72, pp. 938–943, 2006.
[2]
J. Collier, “Bone disorders in chronic liver disease,” Hepatology, vol. 46, no. 4, pp. 1271–1278, 2007.
[3]
R. Paramvir Sokhi, A. Anantharaju, R. Kondaveeti, S. D. Creech, K. K. Islam, and D. H. Van Thiel, “Bone mineral density among cirrhotic patients awaiting liver transplantation,” Liver Transplantation, vol. 10, no. 5, pp. 648–653, 2004.
[4]
H. M. Ahmed, H. K. El-Shereef, S. S. El-Gendi et al., “Leptin, osteocalcin, and bone mineral density in post-hepatitic liver cirrhosis,” Arab Journal of Gastroenterology, vol. 11, no. 3, pp. 130–135, 2010.
[5]
J. D. Collier, M. Ninkovic, and J. E. Compston, “Guidelines on the management of osteoporosis associated with chronic liver disease,” Gut, vol. 50, no. 1, pp. 1–9, 2002.
[6]
M. M. J. Guichelaar, R. Kendall, M. Malinchoc, and J. E. Hay, “Bone mineral density before and after OLT: long-term follow-up and predictive factors,” Liver Transplantation, vol. 12, no. 9, pp. 1390–1402, 2006.
[7]
C. Wibaux, I. Legroux-Gerot, S. Dharancy, E. Boleslawski, N. Declerck, V. Canva, et al., “Evaluation du statut osseux chez les patients en attente d’une greffe hépatique,” Revue Du Rhumatisme, vol. 78, pp. 459–464, 2011.
[8]
“Assessment of fracture risk and its application to screening for postmenopausal osteoporosis,” Report of WHO Study Group 843, World Health Organ Association, Geneva, Switzerland, 1994.
[9]
M. PcDuarte, M. L. F. Farias, H. S. M. Coelho et al., “Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease,” Journal of Gastroenterology and Hepatology, vol. 16, no. 9, pp. 1022–1027, 2001.
[10]
J. George, H. K. Ganesh, S. Acharya et al., “Bone mineral density and disorders of mineral metabolism in chronic liver disease,” World Journal of Gastroenterology, vol. 15, no. 28, pp. 3516–3522, 2009.
[11]
M. Fekih, H. Romdhane, H. Sahli, L. Kallel, S. Matri, S. Karoui, et al., “Les anomalies du métabolisme osseux au cours de la cirrhose,” Gastroentérologie Clinique et Biologique, vol. 33, no. 3, supplement 1, p. 242, 2009.
[12]
A. Z. Salama, A. N. Lotfy, and H. M. El Aeizy, “Evaluation of hepatic osteodystrophy in patients with liver cirrhosis and correlation with severity of liver disease,” Arab Journal of Gastroenterology, vol. 8, no. 1, pp. 10–14, 2007.
[13]
M. Javed, A. Saeed, I. M. Khan et al., “Frequency of osteoporosis in patients with cirrhosis due to hepatitis B and hepatitis C: a study of 100 cases,” Journal of Ayub Medical College, Abbottabad, vol. 21, no. 3, pp. 51–53, 2009.
[14]
J. L. Gonzalez-Calvin, F. Gallego-Rojo, R. Fernandez-Perez, F. Casado-Caballero, E. Ruiz-Escolano, and E. G. Olivares, “Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4325–4330, 2004.
[15]
F. J. Gallego-Rojo, J. L. Gonzalez-Calvin, M. Mu？oz-Torres, J. L. Mundi, R. Fernandez-Perez, and D. Rodrigo-Moreno, “Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis,” Hepatology, vol. 28, no. 3, pp. 695–699, 1998.
[16]
A. Mahmoudi, J. Reboul-Marty, G. Chalès et al., “Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 11, pp. 731–737, 2011.
[17]
A. M. Parfitt, “Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis,” Mineral and Electrolyte Metabolism, vol. 4, no. 6, pp. 273–287, 1980.
[18]
S. Kanzler, M. Baumann, P. Schirmacher et al., “Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β,” Journal of Viral Hepatitis, vol. 8, no. 6, pp. 430–437, 2001.
[19]
S. Ormarsdóttir, ？. Ljunggren, H. Mallmin, H. Brahm, and L. L？？f, “Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease,” Journal of Hepatology, vol. 31, no. 1, pp. 84–90, 1999.
[20]
S. Ormarsdóttir, O. Ljunggren, H. Mallmin, K. Micha？lsson, and L. L？？f, “Increased rate of bone loss at the femoral neck in patients with chronic liver disease,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 1, pp. 43–48, 2002.
[21]
G. Chalès and Guggenbuhl P. Os et foie, Encyclopédie Médico-Chirurgicale 7-034-D-85.
[22]
W. D. Leslie, C. N. Bernstein, and M. S. Leboff, “AGA technical review on osteoporosis in hepatic disorders,” Gastroenterology, vol. 125, no. 3, pp. 941–966, 2003.
[23]
M. A. Karan, N. Erten, C. Tascioglu, A. Karan, D. Sindel, and G. Dilsen, “Osteodystrophy in posthepatitic cirrhosis,” Yonsei Medical Journal, vol. 42, no. 5, pp. 547–552, 2001.
[24]
X. L. Bai, T. B. Liang, L. H. Wu et al., “Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases,” Transplantation Proceedings, vol. 39, no. 10, pp. 3182–3185, 2007.
[25]
American Gastroenterological Association, “American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders,” Gastroenterology, vol. 125, no. 3, pp. 937–940, 2003.
